| Drug Name: | Prazosin (19216-56-9) |
|---|---|
| PubChem ID: | 4893 |
| SMILES: | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC |
| InchiKey: | IENZQIKPVFGBNW-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Antihypertensive Agents, Cardiovascular Agents, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 383.408 |
| LogP | : | 1.7846 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 8 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 106.95 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Alprenolol (13655-52-2) | Hypotension | Synergistic | Synergistic effect of prazosin along with Alprenolol | Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers |
| Nifedipine (21829-25-4) | Blood Pressure Falls Down Sharply | Synergistic | Not Understood | Nifedipine-prazosin interaction in patients with essential hypertension |
| Indomethacin (53-86-1) | Reduces The Blood Pressure-Lowering Effects Of Prazosin | Antagonistic | Indomethacin inhibits the production of hypotensive prostaglandins by the kidney | Studies on the clinical pharmacology of prazosin II: The influence of indomethacin and of propranolol on the action and disposition of prazosin |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category